Debate Renewed: Diabetes drug ups heart risk | Science News



Support credible science journalism.

Subscribe to Science News today.


Debate Renewed: Diabetes drug ups heart risk

11:06am, September 12, 2007

The popular diabetes drug rosiglitazone, marketed as Avandia, more than doubles the long-term risk of heart failure and increases the long-term risk of heart attack by 42 percent, according to a new analysis.

Rosiglitazone initially came under scrutiny earlier this year when an analysis of short-term trials found a 43 percent increase in risk of heart attack among people taking the drug (SN: 6/23/07, p. 397). The Food and Drug Administration called an emergency advisory committee meeting, and in July that group agreed that the drug increases the risk of heart attack. However, the panel recommended that the FDA keep rosiglitazone on the market. The agency is now reviewing data and weighing options on the drug.

This article is available only to subscribing members. Join the Society today or Log in.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content